

### Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

### Collectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

Sep 16 2019, 8:30 AM EDT

### Collectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

Sep 10 2019, 8:00 AM EDT

### Collectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

Sep 4 2019, 8:00 AM EDT

### Stock Overview

Symbol	CLRB	LifeSci Advisors
Exchange	Nasdaq	Monique Kosse
Market Cap	23.02m	Managing Director
Last Price	\$2.45	T: 646-915-3820
52-Week	\$1.22 - \$4.28	monique@lifesciadvisors.com

09/16/2019 03:59 PM EDT

### Investor Relations

### Management Team

#### James Caruso

President, CEO and Director

#### Jarrold Longcor

Chief Business Officer

#### Dov Elefant

Vice President and Chief Financial Officer

---

### Collectar Biosciences, Inc.

100 Campus Drive, Suite 207  
Florham Park, NJ 07932

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.